Sorrento Therapeutics, Inc. (SRNE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | 29.38 Million USD | -26.3% |
| 2021 | 39.87 Million USD | 32.71% |
| 2020 | 30.04 Million USD | 56.53% |
| 2019 | 19.19 Million USD | 72.55% |
| 2018 | 11.12 Million USD | -92.1% |
| 2017 | 140.83 Million USD | 3060.48% |
| 2016 | 4.45 Million USD | 68.79% |
| 2015 | 2.64 Million USD | 48.15% |
| 2014 | 1.78 Million USD | 291.04% |
| 2013 | 455.7 Thousand USD | -21.94% |
| 2012 | 583.77 Thousand USD | 10.32% |
| 2011 | 529.18 Thousand USD | -22.47% |
| 2010 | 682.56 Thousand USD | 12509.79% |
| 2009 | 5413.00 USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q1 | 11.06 Million USD | 491.08% |
| 2023 Q2 | 6.57 Million USD | -40.61% |
| 2022 Q4 | 1.87 Million USD | -79.5% |
| 2022 Q3 | 9.13 Million USD | 58.62% |
| 2022 FY | 29.38 Million USD | -26.3% |
| 2022 Q2 | 5.75 Million USD | -54.41% |
| 2022 Q1 | 12.62 Million USD | 41.81% |
| 2021 Q1 | 10.86 Million USD | 21.8% |
| 2021 Q2 | 10.39 Million USD | -4.41% |
| 2021 Q3 | 5.61 Million USD | -45.92% |
| 2021 Q4 | 8.9 Million USD | 58.46% |
| 2021 FY | 39.87 Million USD | 32.71% |
| 2020 Q3 | 9.08 Million USD | 34.39% |
| 2020 FY | 30.04 Million USD | 56.53% |
| 2020 Q2 | 6.75 Million USD | 27.94% |
| 2020 Q1 | 5.28 Million USD | -54.51% |
| 2020 Q4 | 8.92 Million USD | -1.74% |
| 2019 Q2 | 3.19 Million USD | -16.66% |
| 2019 Q4 | 11.61 Million USD | 2003.62% |
| 2019 FY | 19.19 Million USD | 72.55% |
| 2019 Q1 | 3.83 Million USD | -16.34% |
| 2019 Q3 | 552 Thousand USD | -82.73% |
| 2018 Q2 | 2.68 Million USD | -45.55% |
| 2018 Q4 | 4.58 Million USD | 137.76% |
| 2018 FY | 11.12 Million USD | -92.1% |
| 2018 Q1 | 4.93 Million USD | -74.6% |
| 2018 Q3 | 1.92 Million USD | -28.25% |
| 2017 Q3 | 120.82 Million USD | 3039.13% |
| 2017 Q1 | 3.81 Million USD | 29.28% |
| 2017 FY | 140.83 Million USD | 3060.48% |
| 2017 Q4 | 19.42 Million USD | -83.92% |
| 2017 Q2 | 3.84 Million USD | 1.02% |
| 2016 FY | 4.45 Million USD | 68.79% |
| 2016 Q2 | 607 Thousand USD | -3.5% |
| 2016 Q1 | 629 Thousand USD | -22.73% |
| 2016 Q3 | 1.82 Million USD | 200.66% |
| 2016 Q4 | 2.94 Million USD | 61.48% |
| 2015 Q2 | 859 Thousand USD | 83.55% |
| 2015 FY | 2.64 Million USD | 48.15% |
| 2015 Q3 | 499 Thousand USD | -41.91% |
| 2015 Q4 | 814 Thousand USD | 63.13% |
| 2015 Q1 | 468 Thousand USD | 31.83% |
| 2014 Q1 | 413 Thousand USD | 329.06% |
| 2014 FY | 1.78 Million USD | 291.04% |
| 2014 Q3 | 749 Thousand USD | 182.64% |
| 2014 Q2 | 265 Thousand USD | -35.84% |
| 2014 Q4 | 355 Thousand USD | -52.6% |
| 2013 Q3 | 83.79 Thousand USD | -40.82% |
| 2013 FY | 455.7 Thousand USD | -21.94% |
| 2013 Q1 | 134.06 Thousand USD | 9.9% |
| 2013 Q4 | 96.25 Thousand USD | 14.88% |
| 2013 Q2 | 141.59 Thousand USD | 5.62% |
| 2012 Q3 | 134.5 Thousand USD | -38.05% |
| 2012 FY | 583.77 Thousand USD | 10.32% |
| 2012 Q2 | 217.13 Thousand USD | 97.13% |
| 2012 Q1 | 110.14 Thousand USD | -13.88% |
| 2012 Q4 | 121.98 Thousand USD | -9.31% |
| 2011 Q1 | 235.36 Thousand USD | -54.01% |
| 2011 Q3 | 91.75 Thousand USD | 23.73% |
| 2011 FY | 529.18 Thousand USD | -22.47% |
| 2011 Q2 | 74.15 Thousand USD | -68.49% |
| 2011 Q4 | 127.9 Thousand USD | 39.4% |
| 2010 Q4 | 511.77 Thousand USD | 347.62% |
| 2010 Q1 | - USD | -100.0% |
| 2010 Q2 | 56.46 Thousand USD | 0.0% |
| 2010 Q3 | 114.33 Thousand USD | 102.48% |
| 2010 FY | 682.56 Thousand USD | 12509.79% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | 5413.00 USD | 0.0% |
| 2009 Q4 | 5413.00 USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | -17331.253% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 11854.8% |
| Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 5433.394% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 16609.551% |
| Better Therapeutics, Inc. | -2.72 Million USD | 1176.841% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 2221.805% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | -6852.015% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 228.221% |
| Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Evelo Biosciences, Inc. | - USD | -Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | 2976.867% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 514.368% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 11446.332% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | 55864.925% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 1151.075% |
| Molecular Templates, Inc. | 50.39 Million USD | 41.687% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 24733.891% |
| NexImmune, Inc. | -1.02 Million USD | 2967.103% |
| Orgenesis Inc. | -5.72 Million USD | 613.31% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 214.583% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | 638808.976% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 6118.054% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 12766.81% |
| Trevena, Inc. | 1.45 Million USD | -1919.725% |
| Vaxxinity, Inc. | -2.23 Million USD | 1415.443% |
| Vaccinex, Inc. | -16 Million USD | 283.623% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 6072.967% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | -253018.002% |